一站式68Ga-FAPI/18F-FDG全身PET/CT扫描:可获得更多诊疗一体化信息
这项前瞻性研究纳入40例患者,在一站式协议下先后给予半剂量68Ga-FAPI-04(0.925 MBq/kg)和半剂量18F-FDG(1.85 MBq/kg),用194 cm轴向视野全身PET/CT进行60分钟动态采集。PET D50-60与PET FAPI检出原发肿瘤相近(42 vs 41,P>0.999),但PET D50-60检出转移灶更多(102 vs 60,P<0.001);平均有效剂量9.85±2.19 mSv,与全身18F-FDG PET/CT相似。
要点
- PET D50-60与PET FAPI检出原发肿瘤相近(42 vs 41,P>0.999),转移灶PET D50-60更多(102 vs 60,P<0.001)。
- PET FAPI的靶/肝比、靶/血池比和靶/正常组织比均显著高于PET DUAL(P<0.05)。
- PET D30-40和PET D40-50检出PET D50-60所识别的全部病灶,平均有效剂量9.85±2.19 mSv。
核心结论
- 一站式双放射性示踪剂双低活度成像协议结合了68Ga-FAPI-04与18F-FDG的优势,成像时间更短且辐射暴露更低。
研究设计与样本
- 前瞻性研究,40例患者接受一站式68Ga-FAPI-04 PET(PET FAPI)和双放射性示踪剂PET(PET DUAL),使用194 cm轴向视野全身PET/CT扫描仪。
- 先行半剂量(0.925 MBq/kg)68Ga-FAPI-04 PET/CT,再追加半剂量(1.85 MBq/kg)18F-FDG进行60分钟动态采集。
- PET DUAL按10分钟间隔重建为PET D0-10、PET D10-20、PET D20-30、PET D30-40、PET D40-50和PET D50-60。
- 分析病灶可检出性、靶/本底比、肿瘤分期和总辐射剂量。
- PET FAPI上靶/肝比(TLR)≥3视为成纤维细胞活化蛋白表达充分。
主要发现
- PET D50-60与PET FAPI检出原发肿瘤相近(42 vs 41,P>0.999)。
- PET D50-60检出转移病灶显著多于PET FAPI(102 vs 60,P<0.001)。
- PET FAPI的TLR、靶/血池比和靶/正常组织比均显著高于PET DUAL(P<0.05)。
- PET D10-20、PET D20-30、PET D30-40、PET D40-50和PET D50-60之间病灶可检出性相近(所有P>0.05)。
- PET D30-40和PET D40-50检出PET D50-60所识别的全部病灶;PET D40-50与PET D50-60在TLR、靶/血池比和靶/正常组织比上无显著差异(P>0.05)。
关键数值与推荐
- PET FAPI上靶/肝比(TLR)≥3视为成纤维细胞活化蛋白表达充分。
- PET D50-60与PET FAPI检出原发肿瘤:42 vs 41(P>0.999)。
- PET D50-60与PET FAPI检出转移病灶:102 vs 60(P<0.001)。
- PET FAPI的TLR、靶/血池比和靶/正常组织比均显著高于PET DUAL(P<0.05)。
- 平均有效剂量9.85±2.19 mSv,与全身18F-FDG PET/CT相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This prospective study aims to assess the feasibility of a one-stop imaging protocol using 68 Ga-FAPI-04/ 18 F-FDG dual-radiotracer with dual-low-activity for tumor imaging. PATIENTS AND METHODS: Forty patients underwent one-stop 68 Ga-FAPI-04 PET (PET FAPI ) and dual-radiotracer PET (PET DUAL ) using a total-body PET/CT scanner with a 194-cm axial field of view. After a half-dose (0.925 MBq/kg) 68 Ga-FAPI-04 PET/CT, an additional half-dose (1.85 MBq/kg) of 18 F-FDG was administered for a 60-minute dynamic acquisition. PET DUAL was reconstructed at 10-minute intervals (PET D0-10 , PET D10-20 , PET D20-30 , PET D30-40 , PET D40-50 , and PET D50-60 ). Data of lesion detectability, target-to-background ratios, tumor staging, and total radiation dose were analyzed. A target-to-liver ratio (TLR) ≥ 3 on PET FAPI was considered indicative of sufficient fibroblast activation protein expression. RESULTS: PET D50-60 and PET FAPI showed similar performance in detecting primary tumors (42 vs 41, P > 0.999). However, significantly more metastatic lesions were identified on PET D50-60 compared with PET FAPI (102 vs 60, P < 0.001). PET FAPI demonstrated significantly higher TLR, target-to-blood-pool ratio, and target-to-normal-tissue ratio than PET DUAL ( P < 0.05). Lesion detectability was similar across PET D10-20 , PET D20-30 , PET D30-40 , PET D40-50 , and PET D50-60 (all P 's > 0.05). Notably, PET D30-40 and PET D40-50 detected all lesions identified by PET D50-60 . PET D40-50 showed no significant differences in TLR, target-to-blood-pool ratio, and target-to-normal-tissue ratio compared with PET D50-60 ( P > 0.05). Up to 94.9% of malignant primary lesions exhibited a TLR ≥ 3 on PET FAPI . The average effective dose was 9.85 ± 2.19 mSv, similar to that of a whole-body 18 F-FDG PET/CT. CONCLUSIONS: This one-stop, dual-radiotracer, dual-low-activity imaging protocol combines the strengths of 68 Ga-FAPI-04 and 18 F-FDG, offering a shorter imaging duration and reduced radiation exposure.
引用
- Gao H, Tang H, Zheng Z, et al. One-Stop 68 Ga-FAPI/ 18 F-FDG Total-Body PET/CT Scan : More Theranostics Information Available. Clin Nucl Med. 2025. PMID: 39992887. doi:10.1097/RLU.0000000000005673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。